Phaseline

Targets › GSK3B

GSK3B (Glycogen synthase kinase-3 beta): drug programs, companies and trials

3 programs from 3 companies in 15 trials: 7 Phase 2, 4 Phase 1, 3 Phase 4, 1 Phase 3; Neurology, Oncology, Cardiovascular; next expected readout Dec 2026.

Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. (UniProt, P49841)

Open in Phaseline: the race on GSK3B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AMO PharmaTideglusib
Glycogen synthase kinase-3 beta inhibitor
GSK3BPhase 2Congenital Myotonic Dystrophy; Arrhythmogenic CardiomyopathyDec 2026
Actuate TherapeuticsElraglusib (ING-41)
Glycogen synthase kinase-3 beta inhibitor
GSK3BPhase 2Cancer; Pancreatic Adenocarcinoma; Salivary Gland Cancer–
Alzamend NeuroLithium Carbonate (AL001)
Inositol-1(or 4)-monophosphatase 1 inhibitor; Glycogen synthase kinase-3 inhibitor
IMPA1, GSK3A, GSK3BPhase 1Bipolar I Disorder; Healthy; Bipolar II Disorder; Depression, Bipolar …Dec 2026

Conditions

Pancreatic Adenocarcinoma (2) Congenital Myotonic Dystrophy (1) Arrhythmogenic Cardiomyopathy (1) Bipolar I Disorder (1) Healthy (1) Bipolar II Disorder (1) Depression, Bipolar (1) Bipolar Depression (1) Cornelia De Lange Syndrome (1) Cognitive Impairment (1) Parkinson Disease (1) Proven Pathogenic or Probably Pathogenic TBR1 Variant (1)

Modalities

small molecule (2), mixed (1)

Companies

AMO Pharma (1) Alzamend Neuro (1) Actuate Therapeutics (1)

Related targets

IMPA1 (1) GSK3A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.